Repligen Corporation (RGEN) is a healthcare stock that has risen 27% year-to-date and 57% over the last 12 months. It has good earnings momentum with back-to-back strong quarterly gains of 6.2% and 6%. The stock has risen consistently with minor corrections throughout 2017.
Recommendation Go long RGEN with a buy stop above round $40 number at $40.25 and add to you long at the weekly cup base trigger of $42.58 that began July 2015. (Breakout above cup would achieve all-time highs.) RGEN has demonstrated superior relative strength and once the pharma sector establishes itself as a leader once again this name should be well positioned to outperform.